FDA Approves Foundayo Oral GLP-1 Agonist for Weight Management

The U.S. Food and Drug Administration (FDA) has granted approval for Foundayo (orforglipron), a new oral medication developed by Eli Lilly and Company for weight management. Foundayo is the first GLP-1 receptor agonist in pill form that can be taken at any time of day without restrictions related to food or water intake, distinguishing it from other treatments in its class.

The approval marks a significant development in the field of weight loss medications, as GLP-1 receptor agonists are typically administered via injection and often require specific timing or dietary considerations. Foundayo offers an alternative for individuals seeking a more convenient option for managing their weight. The FDA’s decision follows clinical trials evaluating the safety and efficacy of orforglipron, which demonstrated positive outcomes in terms of weight reduction among participants. Further details regarding dosage, availability, and pricing have not yet been disclosed.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: April 1, 2026

Author

GOAI